Indianapolis-based Lilly to present new oncology data at Oct. 23–27 ESMO Congress in Madrid

Eli Lilly said it will present new oncology data at the ESMO Congress taking place Oct. 23–27, 2026, in Madrid, Spain. Lilly’s investor release lists scheduled items including: a Sofetabart mipitecan (Sofe‑M) poster on Friday, Oct. 23, 15:15–16:00 CET; a Sofe‑M rapid oral on Saturday, Oct. 24, 8:30–10:00 CET (Gynecological cancers session); the postMONARCH Phase 3 overall survival rapid oral on Saturday, Oct. 24, 10:15–11:45 CET (Breast cancer, advanced stage session); an updated integrated analysis of olomorasib as a rapid oral on Sunday, Oct. 25, 8:30–10:00 CET (NSCLC metastatic session); and an olomorasib poster (Poster #2683P) on Monday, Oct. 26, 12:00–12:45 CET.

Lilly’s release notes that Sofetabart mipitecan (Sofe‑M; LY4170156) has FDA Breakthrough Therapy Designation for platinum‑resistant ovarian cancer and is being evaluated in the Phase 3 FRAmework‑01 trial with ENGOT, the GOG Foundation and APGOT. The company described olomorasib (LY3537982) as an investigational, oral second‑generation KRAS G12C inhibitor and stated KRAS G12C mutations occur in about 13% of patients with NSCLC and 1–3% of patients with other solid tumors.

Report a correction · Editorial standards · Our source directory

BusinessIndy examines this development and its implications for Indiana businesses and communities using the linked sources.